or Try an Advanced Search...

    Technical Analysis for ATRA - Atara Biotherapeutics, Inc.

    Grade Last Price % Change Price Change
    F 8.36 -1.65% -0.14
    ATRA closed down 1.65 percent on Monday, July 1, 2024, on 1.89 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ATRA trend table...
    Date Alert Name Type % Chg
    1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Slingshot Bearish Bearish Swing Setup -1.65%
    Pocket Pivot Bullish Swing Setup -1.65%
    Volume Surge Other -1.65%
    Wide Bands Range Expansion -1.65%
    Older End-of-Day Signals for ATRA ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 4 hours ago
    60 Minute Opening Range Breakout about 4 hours ago
    Down 2 % about 6 hours ago
    Possible NR7 about 6 hours ago
    Possible Inside Day about 6 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ATRA Chart by TradingView
    Basic chart:

    Profile

    Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease

    Is ATRA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 21 Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
    Jun 17 Atara Biotherapeutics announces reverse split to regain Nasdaq compliance
    Jun 17 Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
    Jun 12 Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
    Jun 5 Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    May 29 Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
    May 23 Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
    May 22 GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
    May 20 Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise
    May 20 Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
    See more ATRA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 63.375
    52 Week Low 4.965
    Average Volume 82,415
    200-Day Moving Average 19.95
    50-Day Moving Average 14.05
    20-Day Moving Average 11.17
    10-Day Moving Average 8.61
    Average True Range 1.26
    RSI (14) 35.90
    ADX 38.29
    +DI 18.27
    -DI 25.79
    Chandelier Exit (Long, 3 ATRs) 11.64
    Chandelier Exit (Short, 3 ATRs) 10.84
    Upper Bollinger Bands 16.52
    Lower Bollinger Band 5.82
    Percent B (%b) 0.24
    BandWidth 95.80
    MACD Line -1.92
    MACD Signal Line -1.72
    MACD Histogram -0.2031
    Fundamentals Value
    Market Cap 852.07 Million
    Num Shares 102 Million
    EPS -2.78
    Price-to-Earnings (P/E) Ratio -3.01
    Price-to-Sales 18.35
    Price-to-Book 1.97
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.25
    Resistance 3 (R3) 9.29 9.05 9.10
    Resistance 2 (R2) 9.05 8.82 9.02 9.05
    Resistance 1 (R1) 8.70 8.68 8.58 8.66 9.00
    Pivot Point 8.46 8.46 8.40 8.43 8.46
    Support 1 (S1) 8.11 8.23 7.99 8.07 7.72
    Support 2 (S2) 7.87 8.09 7.84 7.67
    Support 3 (S3) 7.52 7.87 7.62
    Support 4 (S4) 7.48